What's Happening?
Merck has announced the results of the Phase 3 KEYNOTE-B96 trial, which demonstrated that the combination of KEYTRUDA (pembrolizumab) with paclitaxel, with or without bevacizumab, significantly improved overall survival in patients with platinum-resistant
recurrent ovarian cancer. This trial, presented at the European Society of Gynaecological Oncology 2026 Congress, showed that the regimen reduced the risk of death by 18% compared to the standard treatment of paclitaxel with or without bevacizumab. The study involved 643 patients and highlighted a median overall survival of 17.7 months for those receiving the KEYTRUDA regimen, compared to 14.0 months for the control group. The European Medicines Agency's Committee for Medicinal Products for Human Use has also recommended approval of this regimen for certain patients with PD-L1 expressing tumors.
Why It's Important?
The findings from the KEYNOTE-B96 trial are significant as they offer a new potential treatment option for patients with platinum-resistant ovarian cancer, a group that typically has limited options and poor prognosis. The improved survival rates could lead to changes in treatment protocols and provide hope for better outcomes in this challenging cancer type. The approval by regulatory bodies like the FDA and the positive opinion from the European Medicines Agency further validate the clinical benefits of this regimen, potentially influencing treatment standards globally. This development underscores Merck's commitment to advancing cancer treatment and addressing unmet needs in women's cancers.
What's Next?
Following the positive trial results and regulatory endorsements, Merck is likely to focus on the broader implementation of this treatment regimen in clinical settings. The company may also continue to explore additional combinations and indications for KEYTRUDA in other cancer types. Healthcare providers and oncologists will need to consider these findings when developing treatment plans for patients with platinum-resistant ovarian cancer. Further research and real-world data will be crucial to understanding the long-term benefits and potential side effects of this treatment combination.
